#United States #healthcare #Salt Lake City #Lipocine #LPCN

Lipocine's Upcoming Presentation at A.G.P. Annual Showcase

On May 20, 2026, Lipocine Inc. (NASDAQ: LPCN), a frontrunner in biopharmaceutical innovations, is set to participate in a fireside chat at the A.G.P.'s Annual Virtual Healthcare Company Showcase. This event will serve as a platform to discuss Lipocine's groundbreaking technology and its current and future drug candidates.

A Glimpse into Lipocine's Innovations

Lipocine Inc. specializes in enhancing therapeutics by utilizing its proprietary technology platform aimed at improving oral drug delivery. This approach is vital in meeting significant unmet medical needs in various therapeutic areas. The company's product pipeline includes a range of candidates that are positioned to address numerous health issues, providing patients with effective and user-friendly options.

Some of the prominent drug candidates in development include:

• - LPCN 1154: Designed for the treatment of postpartum depression, targeting women who face this overwhelming condition!
• - LPCN 2201: Aimed at managing major depressive disorder, a common but often debilitating illness.
• - LPCN 2101: Focused on epilepsy treatment, promising better management of this neurological condition.
• - LPCN 2203: Targeted for essential tremor management, providing relief for affected individuals.
• - LPCN 2401: An innovative approach to improve body composition in obesity management.
• - LPCN 1148: This candidate is focused on managing symptoms associated with liver cirrhosis, an often serious condition.
• - LPCN 1107: Designed for the prevention of preterm birth, aiming to improve outcomes for vulnerable pregnancies.
• - TLANDO: Notably, TLANDO is an FDA-approved oral prodrug of testosterone for men with testosterone deficiency issues.

The Significance of the A.G.P. Showcase

The A.G.P. Annual Virtual Healthcare Company Showcase is poised to provide a valuable platform for Lipocine to share insights on their advancements and drug development strategies. Scheduled for 3 PM ET on May 20, potential investors and interested parties can register to attend this engaging fireside chat. This event highlights the significant strides Lipocine has made in biopharmaceutical research and development.

What Lies Ahead for Lipocine

In a rapidly evolving healthcare landscape, Lipocine's commitment to leveraging its proprietary technology to create patient-friendly treatment options positions it uniquely in the biopharmaceutical field. The company focuses on large addressable markets with significant unmet medical needs, which reflects its strategic vision to impact lives positively.

As the healthcare industry continues to seek innovative solutions, Lipocine’s impressive drug pipeline and its active participation in events like the A.G.P. showcase underscore its dedication to pioneering therapeutic advancements. Interested stakeholders should stay tuned for further developments, as Lipocine continues on its mission to provide accessible and effective healthcare solutions.

For more details about Lipocine and its innovative offerings, visit Lipocine's website.